Kynurenine metabolism in multiple sclerosis

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Objective - Excitatory amino acid receptors are involved in the normal physiology of the brain, and may play a role in the pathogenesis of neurological disorders such as Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, etc. It has been demonstrated that the blockade of one of these receptors ameliorates the symptoms of experimental allergic encephalomyelitis, an animal model of multiple sclerosis (MS). In a recent study, a decreased level of kynurenic acid was found in the cerebrospinal fluid of patients with MS. The only known endogenous excitotoxin receptor antagonist is the tryptophan metabolite kynurenic acid. Another metabolite is quinolinic acid, which exerts different action: it is an excitotoxin receptor agonist. The ratio of these two metabolites is determined by the activities of kynurenine aminotransferase I and II (KAT I and KAT II). In this study, we measured the activities of these enzymes and the concentration of kynurenic acid in the red blood cells (RBC) and in the plasma of patients with MS. KAT activities were detected both in the RBC and in the plasma. As compared with the control subjects, the KAT I and KAT II activities were significantly higher in the RBC of the patients. The concentration of kynurenic acid is elevated in the plasma of MS patients, and there is a tendency to an elevation in the RBC. These changes may indicate a compensatory protective mechanism against excitatory neurotoxic effects. Our data demonstrate the involvement of the kynurenine system in the pathogenesis of MS, which may predict a novel therapeutic intervention.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalActa Neurologica Scandinavica
Volume112
Issue number2
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Kynurenine
Kynurenic Acid
Multiple Sclerosis
kynurenine-oxoglutarate transaminase
Erythrocytes
Neurotoxins
lissamine rhodamine B
Quinolinic Acid
Autoimmune Experimental Encephalomyelitis
Huntington Disease
Amyotrophic Lateral Sclerosis
Glutamate Receptors
Nervous System Diseases
Tryptophan
Parkinson Disease
Cerebrospinal Fluid
Animal Models
Brain
Enzymes

Keywords

  • Excitotoxicity
  • Kynurenic acid
  • Kynurenine aminotransferase
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Kynurenine metabolism in multiple sclerosis. / Hartai, Z.; Klivényi, P.; Janáky, T.; Penke, B.; Dux, L.; Vécsei, L.

In: Acta Neurologica Scandinavica, Vol. 112, No. 2, 08.2005, p. 93-96.

Research output: Contribution to journalArticle

@article{741c2b0693d540c58021378ae8abc5bb,
title = "Kynurenine metabolism in multiple sclerosis",
abstract = "Objective - Excitatory amino acid receptors are involved in the normal physiology of the brain, and may play a role in the pathogenesis of neurological disorders such as Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, etc. It has been demonstrated that the blockade of one of these receptors ameliorates the symptoms of experimental allergic encephalomyelitis, an animal model of multiple sclerosis (MS). In a recent study, a decreased level of kynurenic acid was found in the cerebrospinal fluid of patients with MS. The only known endogenous excitotoxin receptor antagonist is the tryptophan metabolite kynurenic acid. Another metabolite is quinolinic acid, which exerts different action: it is an excitotoxin receptor agonist. The ratio of these two metabolites is determined by the activities of kynurenine aminotransferase I and II (KAT I and KAT II). In this study, we measured the activities of these enzymes and the concentration of kynurenic acid in the red blood cells (RBC) and in the plasma of patients with MS. KAT activities were detected both in the RBC and in the plasma. As compared with the control subjects, the KAT I and KAT II activities were significantly higher in the RBC of the patients. The concentration of kynurenic acid is elevated in the plasma of MS patients, and there is a tendency to an elevation in the RBC. These changes may indicate a compensatory protective mechanism against excitatory neurotoxic effects. Our data demonstrate the involvement of the kynurenine system in the pathogenesis of MS, which may predict a novel therapeutic intervention.",
keywords = "Excitotoxicity, Kynurenic acid, Kynurenine aminotransferase, Multiple sclerosis",
author = "Z. Hartai and P. Kliv{\'e}nyi and T. Jan{\'a}ky and B. Penke and L. Dux and L. V{\'e}csei",
year = "2005",
month = "8",
doi = "10.1111/j.1600-0404.2005.00442.x",
language = "English",
volume = "112",
pages = "93--96",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Kynurenine metabolism in multiple sclerosis

AU - Hartai, Z.

AU - Klivényi, P.

AU - Janáky, T.

AU - Penke, B.

AU - Dux, L.

AU - Vécsei, L.

PY - 2005/8

Y1 - 2005/8

N2 - Objective - Excitatory amino acid receptors are involved in the normal physiology of the brain, and may play a role in the pathogenesis of neurological disorders such as Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, etc. It has been demonstrated that the blockade of one of these receptors ameliorates the symptoms of experimental allergic encephalomyelitis, an animal model of multiple sclerosis (MS). In a recent study, a decreased level of kynurenic acid was found in the cerebrospinal fluid of patients with MS. The only known endogenous excitotoxin receptor antagonist is the tryptophan metabolite kynurenic acid. Another metabolite is quinolinic acid, which exerts different action: it is an excitotoxin receptor agonist. The ratio of these two metabolites is determined by the activities of kynurenine aminotransferase I and II (KAT I and KAT II). In this study, we measured the activities of these enzymes and the concentration of kynurenic acid in the red blood cells (RBC) and in the plasma of patients with MS. KAT activities were detected both in the RBC and in the plasma. As compared with the control subjects, the KAT I and KAT II activities were significantly higher in the RBC of the patients. The concentration of kynurenic acid is elevated in the plasma of MS patients, and there is a tendency to an elevation in the RBC. These changes may indicate a compensatory protective mechanism against excitatory neurotoxic effects. Our data demonstrate the involvement of the kynurenine system in the pathogenesis of MS, which may predict a novel therapeutic intervention.

AB - Objective - Excitatory amino acid receptors are involved in the normal physiology of the brain, and may play a role in the pathogenesis of neurological disorders such as Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, etc. It has been demonstrated that the blockade of one of these receptors ameliorates the symptoms of experimental allergic encephalomyelitis, an animal model of multiple sclerosis (MS). In a recent study, a decreased level of kynurenic acid was found in the cerebrospinal fluid of patients with MS. The only known endogenous excitotoxin receptor antagonist is the tryptophan metabolite kynurenic acid. Another metabolite is quinolinic acid, which exerts different action: it is an excitotoxin receptor agonist. The ratio of these two metabolites is determined by the activities of kynurenine aminotransferase I and II (KAT I and KAT II). In this study, we measured the activities of these enzymes and the concentration of kynurenic acid in the red blood cells (RBC) and in the plasma of patients with MS. KAT activities were detected both in the RBC and in the plasma. As compared with the control subjects, the KAT I and KAT II activities were significantly higher in the RBC of the patients. The concentration of kynurenic acid is elevated in the plasma of MS patients, and there is a tendency to an elevation in the RBC. These changes may indicate a compensatory protective mechanism against excitatory neurotoxic effects. Our data demonstrate the involvement of the kynurenine system in the pathogenesis of MS, which may predict a novel therapeutic intervention.

KW - Excitotoxicity

KW - Kynurenic acid

KW - Kynurenine aminotransferase

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=22344443211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22344443211&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0404.2005.00442.x

DO - 10.1111/j.1600-0404.2005.00442.x

M3 - Article

C2 - 16008534

AN - SCOPUS:22344443211

VL - 112

SP - 93

EP - 96

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 2

ER -